Share on StockTwits

InterMune (NASDAQ:ITMN) EVP Jonathan A. Leff sold 1,153 shares of InterMune stock on the open market in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $38.78, for a total transaction of $44,713.34. Following the completion of the transaction, the executive vice president now directly owns 46,321 shares in the company, valued at approximately $1,796,328. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on ITMN. Analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Separately, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Finally, analysts at Leerink Swann upgraded shares of InterMune from a “market perform” rating to an “outperform” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. InterMune presently has an average rating of “Buy” and an average price target of $39.08.

InterMune (NASDAQ:ITMN) traded up 2.28% during mid-day trading on Thursday, hitting $40.87. The stock had a trading volume of 1,774,305 shares. InterMune has a one year low of $9.32 and a one year high of $41.24. The stock’s 50-day moving average is $35.49 and its 200-day moving average is $24.37. The company’s market cap is $4.041 billion.

InterMune (NASDAQ:ITMN) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.59) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter last year, the company posted ($0.64) earnings per share. InterMune’s revenue was up 188.6% compared to the same quarter last year. On average, analysts predict that InterMune will post $-2.34 earnings per share for the current fiscal year.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.